Valeant Sheds Staff, Creates Executive Panel After Bausch & Lomb Deal
This article was originally published in The Tan Sheet
Executive Summary
The fast-growing, Canadian specialty pharma will shed more than 2,700 jobs as it absorbs Bausch & Lomb, as part of an endeavor to save $800 million. CEO Mike Pearson’s note to employees describes a new organizational philosophy, with restructured management and business units.
You may also be interested in...
Actavis’ Brent Saunders And Paul Bisaro Talk Innovation Vs. Discovery
Incoming CEO and executive chairman of the Actavis/Forest colossus discuss the end of “me-too” drugs and the future of R&D in an interview with “The Pink Sheet” DAILY.
Valeant Keeps Door Open For Consumer Products Acquisitions
The specialty pharmaceutical firm’s consumer products portfolio has grown with the closing of its ophthalmology firm Bausch & Lomb acquisition. Valeant is not ruling out more acquisitions in the consumer products space, CEO J. Michael Pearson says.
Valeant Keeps Door Open For Consumer Products Acquisitions
The specialty pharmaceutical firm’s consumer products portfolio has grown with the closing of its ophthalmology firm Bausch & Lomb acquisition. Valeant is not ruling out more acquisitions in the consumer products space, CEO J. Michael Pearson says.